ASP-0739(Astellas Pharma Inc)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameASP-0739(Astellas Pharma Inc)
Drug Alias NameASP-0739
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionImmunologic cytotoxicityCell replacements
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAstellas Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesAstellas Pharma Global Development Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A